Home / Treatments / High Intensity Focused Ultrasound
High Intensity Focused Ultrasound denials: what the review data shows
Independent reviewers have decided 42 published cases where an insurer denied High Intensity Focused Ultrasound — and they overturned the insurer 26.2% of the time. A denial for High Intensity Focused Ultrasound is a starting position, not a final answer.
Published decisions
42
2001–2026
Overturned
26.2%
11 denials reversed
By condition
Published outcomes when High Intensity Focused Ultrasound was denied for these conditions.
| Condition | Decisions | Overturned |
|---|---|---|
| Prostate Cancer | 41 | 24.4% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 26 | 19.2% |
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 16 | 37.5% |
Typical time to a decision
7 days
Most land between 4 and 17 days
Handled as urgent
64.3%
Expedited when a delay would cause harm
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Findings: The physician reviewer found thatNature of Statutory Criteria/Case Summary: The patient requested reimbursement for high-intensity focused ultrasound (HIFU).In the review of the available records and the current literature for the treatment of organ-confined prostate cancer, ablation of malignant prostate tissue, transrectal, with high intensity-focused ultrasound (HIFU), including ultrasound guidance of the prostate is a recommended therapy for the treatment of this patient's prostate cancer. The American Urological Association (AUA) guidelines state that ablation may be considered in select, appropriately informed patients. The authors indicated that patients being considered for ablation should have intermediate-risk prostate cancer.
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for high-intensity focused ultrasound (HIFU) services. The American Urological Association (AUA) guidelines on clinically localized prostate cancers note that ablation may be considered in select, appropriately informed patients and that patients being considered for ablation should have intermediate-risk prostate cancer. Based on these guidelines and other studies, high-intensity focused ultrasound is now a standard treatment option for certain types of prostate cancer and can help patients avoid the complications of prostatectomy. In this case, the patient has been diagnosed with Gleason 3+4=7 prostate cancer based on a prostate biopsy obtained due to an elevated PSA. The record reveals that the patient had a UCSF-CAPRA consistent with intermediate-risk disease.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for high-intensity focused ultrasound (HIFU). Findings: The physician reviewer found that HIFU is considered a minimally invasive treatment option for localized prostate cancer that uses focused ultrasound energy to locally heat and destroy diseased tissue through ablation. HIFU is often utilized in patients who are unable to tolerate surgery or radiation treatment. Other conventional treatment options for the management of patients with early-stage localized prostate cancer include radical prostatectomy, cryotherapy, external beam radiation treatment, and brachytherapy radiation treatment. There are several studies that have demonstrated good functional outcomes and a well-tolerated side effect profile following HIFU treatment in the setting of localized prostate cancer.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for high-intensity focused ultrasound (HIFU). HIFU consists of focused ultrasound waves emitted from a transducer that cause tissue damage by mechanical and thermal effects as well as by cavitation. HIFU has been increasingly used for the treatment of patients with localized prostate cancer. Potential candidates are patients with low-to-moderate risk prostate cancer. The available literature primarily consists of prospective case series and retrospective studies showing short- to intermediate-term outcomes for patients with localized prostate cancer. However, there is a paucity of prospective randomized controlled trials with long-term follow-up available for analysis.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for High Intensity Focused Ultrasoundwhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.